The Overall Survival and Safety of Men with Metastatic Hormone-Sensitive Prostate Cancer Treated with Combination Therapy of Novel Androgen Receptor Antagonists and Androgen-Deprivation Therapy: A Systematic Review and Meta-Analysis
Table 4
Safety outcomes of all the included studies.
Events
Latitude
Stampede
Arches
Enzamet
Titan
Arasens
sum up
Test
Control
Test
Control
Test
Control
Test
Control
Test
Control
Test
Control
Test
Control
Any AE
558/597 (93)
557/602 (93)
943/948 (99)
950/960 (99)
487/572 (85.5)
493/574 (85.9)
563/563 (100)
548/558 (98)
507/524 (96.8)
509/527 (96.6)
649/652 (99.5)
643/650 (98.9)
3707/3856 (96.1)
3700/3871 (95.6)
Grade 3 or 4 AE
374/597 (63)
287/602 (48)
443/948 (47)
315/960 (33)
139/572 (24.3)
147/574 (25.6)
44/563 (8)
47/558 (8)
221/524 (42.2)
215/527 (40.8)
210/652 (32.2)
207/650 (31.8)
1431/3856 (37.1)
1218/3871 (31.5)
Any serious AEs
165/597 (28)
146/602 (24)
NR
NR
22/572 (3.8)
16/574 (2.8)
235/563 (42)
189/558 (34)
104/524 (19.8)
107/527 (20.3)
292/652 (44.8)
275/650 (42.3)
818/2908 (28.1)
733/2911 (25.2)
AEs leading to death
28/597 (5)
24/602 (4)
NR
NR
14/572 (2.4)
10/574 (1.7)
NR
NR
10/524 (1.9)
16/527 (3)
27/652 (4.1)
26/650 (4)
79/2345 (3.4)
76/2353 (3.2)
AE, adverse event; NR, not reported. The data were presented as the median case number/total number (incidence × 100).
